REG - IXICO plc - Contract Win

IXICOAnnouncement

04/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220804:nRSD7872Ua&default-theme=true

RNS Number : 7872U  IXICO plc  04 August 2022

IXICO plc

("IXICO" or the "Company")

 

Contract win for a Phase 2 Parkinson's disease trial worth over £0.8m

 

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent
insights in neuroscience, announces that it has been selected by a leading
European biopharmaceutical company to provide MRI and DAT-SPECT imaging
services for a Phase 2 clinical trial in Parkinson's disease ('PD').

 

This is the second study award with this client in the last twelve months.
IXICO will provide radiology and quantitative analysis services to support
patient selection, safety, and efficacy analysis. The trial is expected to be
delivered over a period of four and a half years.

 

Since its inception in 2004, IXICO has built an extensive portfolio of
proprietary imaging data management and analysis technologies for
investigation of neurological disorders across the entire drug development
lifecycle, from phase I through to commercialisation.

 

 

Giulio Cerroni, CEO of IXICO, commented: "We are delighted to be awarded this
contract to support the development of this promising investigational drug in
PD.  Our success in being awarded a second study with this client,
demonstrates the momentum we are building in expanding into a broader range of
neurodegenerative therapeutic indications.  Our mission is to support our
current and prospective clients in their efforts to bring potential treatments
to patients suffering from neurological disorders, and this contract is an
example of the confidence that increasing numbers of companies are placing in
IXICO as their trusted neuroimaging partner for their important CNS studies."

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning AI data
analytics, at scale, through its remote access TrialTracker technology
platform, to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for the Company's pharmaceutical
clients.

 

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUOVKRUBUWRRR